OptimizeRx Expects FY23 Revenues To Be Between $68M-$70M Vs. Consensus Of $60.51M; And Adjusted EBITDA Of $3M-$4M
Portfolio Pulse from Benzinga Newsdesk
OptimizeRx has updated its FY23 revenue forecast to between $68M-$70M, exceeding the consensus of $60.51M. The company also expects its adjusted EBITDA to be between $3M-$4M. Preliminary guidance for 2024 indicates revenues of at least $110M with an adjusted EBITDA margin of at least 10%.
November 06, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
OptimizeRx has raised its FY23 revenue forecast, which is expected to positively impact its stock price in the short term.
OptimizeRx has raised its revenue forecast for FY23, which is significantly higher than the consensus. This indicates strong performance and growth, which is likely to be viewed positively by investors and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100